• Amdocs Limited recently reported its third-quarter 2026 results, with revenue rising to US$1,174.9 million from US$1,144.44 million a year earlier, while net income fell to US$62.17 million from US$154 million and diluted EPS from continuing operations declined to US$0.59 from US$1.39.
• Alongside this mixed earnings picture, Amdocs highlighted a growing pipeline of AI-enabled modernization work, including a 10-year Liberty Latin America engagement and new projects with Sunrise, Cielo, Optimum, PLDT, and Vivo that reinforce its role in digital and AI transformation for telecom and payments providers.
• We’ll now examine how the new 10-year Liberty Latin America AI agreement shapes Amdocs’ investment narrative and longer-term business profile.

The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 16 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.

Amdocs Investment Narrative Recap

To stay invested in Amdocs, you need to believe its core telecom and media relationships can support steady software and services demand while AI modernization and managed services deepen customer ties. The latest quarter’s revenue growth but sharply lower net income highlights execution and cost pressures, so the key near term catalyst is converting its AI and cloud pipeline into higher margin contracts. The biggest current risk is that large clients defer or resize projects, and this earnings miss does little to ease that concern.

The new 10 year Liberty Latin America engagement is the clearest link to that catalyst, since it puts Amdocs’ agentic aOS platform at the center of a broad IT modernization and AI operations shift. Together with upgrades at Sunrise, Vivo and PLDT, it reinforces the view that operators are committing to long duration, AI enabled managed services, even as near term profitability remains under pressure.

Yet behind the promise of long contracts, investors should be aware of how concentrated spending decisions at a few large operators could...

Amdocs' narrative projects $5.2 billion revenue and $832.7 million earnings by 2029. This requires 4.0% yearly revenue growth and about a $287 million earnings increase from $545.8 million today.

Uncover how Amdocs' forecasts yield a $81.21 fair value, a 47% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were expecting Amdocs to reach about US$5.2 billion of revenue and roughly US$842 million of earnings by 2029, which assumes AI and cloud investments materially lift margins, while the latest quarter’s weaker profit and heavy AI spending remind you that these upbeat scenarios can differ sharply from more cautious views and may be revised as the impact of deals like Liberty Latin America becomes clearer.

Explore 6 other fair value estimates on Amdocs - why the stock might be worth just $70.84!

Decide For Yourself

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your Amdocs research is our analysis highlighting 5 key rewards that could impact your investment decision.
• Our free Amdocs research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Amdocs' overall financial health at a glance.

No Opportunity In Amdocs?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Uncover the next big thing with 19 elite penny stocks that balance risk and reward.
• AI is about to change healthcare. These 42 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Capitalize on the AI infrastructure supercycle with our selection of the 56 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.